US FDA approves Novartis' kidney disease drug
07/08/2024 19:20
Aug 7 (Reuters) - The U.S. Food and Drug Administration has approved the use of Novartis' NOVN.S drug to treat patients with a type of kidney disease, the health regulator's website showed on Wednesday. (Reporting by Sriparna Roy in Bengaluru; Editing by Shilpi Majumdar) ((Sriparna.Roy@thomsonreuters.com;))
Recent news on Calliditas Therapeutics AB
See all newsBrief: Calliditas To Be Delisted From Nasdaq Stockholm
Brief: Calliditas Therapeutics Takes Certain Corporate Actions Following Announcement By Asahi Kasei
Brief: Asahi Kasei Corp: Notice Regarding Results Of Tender Offer For Shares Of Calliditas Therapeutics AB And Transfer Of Subsidiary
Calliditas Therapeutics AB reports results for the quarter ended in January - Earnings Summary
Brief: Calliditas Q2 Sales Beat Expectations